Biomarker Screening for Targeted Bifidobacteria Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack the ability to predict which subjects among the wider population will respond better to the administration of probiotics and prebiotics for weight management and metabolic disorder treatment.
Innovation Solution
A method involving the measurement and comparison of specific biomarkers such as hPAI1 Total, bile acids, and certain bacteria levels in a subject to identify an increased probability of a beneficial clinical response to Bifidobacterium strains, followed by targeted administration of these strains for managing weight and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotics and prebiotics are administered to the wider population for weight management and metabolic disorder treatment, then health benefits may be achieved, but the inability to predict which subjects will respond better reduces treatment effectiveness and wastes resources
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels (such as hPAI-1, bile acids, and gut microbiota composition) before probiotic administration to predict which subjects will respond beneficially. This pre-assessment allows identification of suitable candidates in advance, ensuring that only those likely to benefit receive the treatment, thereby improving reliability and preventing resource waste.
2Measurement precision
If biomarker measurement and comparison methods are implemented to identify suitable subjects, then treatment precision and effectiveness improve, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic process into distinct steps: measuring specific biomarkers (hPAI-1, bile acids, gut microbiota), comparing each against established thresholds, and integrating results to determine suitability. This segmented approach breaks down the complex diagnostic task into manageable components, improving measurement precision while making the process systematically implementable.
Solution Approach 2:
The patent applies parameter changes by focusing on specific measurable parameters (biomarker levels) that correlate with probiotic response. By establishing threshold values for these parameters and comparing subject values against them, the method transforms a complex predictive problem into a series of straightforward parameter comparisons, enhancing accuracy without excessive complexity.
3Productivity
If targeted administration of Bifidobacterium strains is implemented based on biomarker identification, then weight management and metabolic disorder treatment effectiveness improve, but the need for additional testing and screening increases time and resource requirements
Solution Approach 1:
The patent applies preliminary action by conducting biomarker assessments before treatment to identify suitable candidates in advance. Although this requires initial testing time, it prevents wasted time on ineffective treatments by ensuring only responsive subjects receive Bifidobacterium administration, ultimately improving overall productivity through targeted effective treatment.
Solution Approach 2:
The patent applies copying by using established biomarker profiles and threshold values from prior research and clinical data as reference standards. These pre-established criteria serve as templates for evaluating new subjects, allowing rapid assessment without requiring de novo complex studies, thus reducing screening time while maintaining accuracy.
Data Source
AI summary
This invention relates to a method of identifying a subject having an increased probability of having a beneficial clinical response to administration of a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof to said subject, by measuring the level of some specific biomarkers in said subject.